Dirk Trommeshauser

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

Tim Heise, Eva U. Graefe-Mody, S. Hüttner et al. · Diabetes Obesity and Metabolism · 2009 · 175 citations

Medicine, Pharmacokinetics, Pharmacology +16

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Journal of Clinical Oncology · 2008 · 158 citations · Full text

Pharmacy, Oncology, Pharmacology +14

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Andreas Hochhaus et al. · Clinical Cancer Research · 2010 · 87 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours

Annette Frost, K. Mross, Simone Steinbild et al. · Current Oncology · 2012 · 84 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Ibuprofen Extrudate, a Novel, Rapidly Dissolving Ibuprofen Formulation: Relative Bioavailability Compared to Ibuprofen Lysinate and Regular Ibuprofen, and Food Effect on All Formulations

Matthias Klueglich, Arne Ring, Stefan Scheuerer et al. · The Journal of Clinical Pharmacology · 2005 · 65 citations

Pharmacy, Pharmaceutics, Pharmacology +17